MedTrace Logo

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

NCT00537056 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Conditions

  • Kidney Neoplasms
  • Carcinoma, Renal Cell
  • Kidney (Renal Cell) Cancer

Interventions

PROCEDURE

FDG PET CT

nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body

PROCEDURE

DCE MRI

DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).

DRUG

F-18 Fluoro-deoxi-glucose

15 mCi iv

DRUG

Gadolinium-DTPA

0.1 mmol/kg iv

DRUG

Sunitinib

50 mg/day po

Sponsors & Collaborators

Principal Investigators

  • Dr Andrew Quon · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-10-31
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537056 on ClinicalTrials.gov